Tirzepatide 30mg

Compound Overview

Tirzepatide 30mg is a lyophilized peptide preparation supplied by Amino Apex for qualified laboratory research. Tirzepatide, also identified as LY3298176, is a 39-amino-acid synthetic peptide engineered from the sequence of native GIP and designed to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).

Its dual-receptor pharmacology has made tirzepatide an important research compound for investigating incretin receptor signaling, peptide-receptor selectivity, endocrine pathway integration, glucose-responsive cellular signaling, and metabolic regulation.

Tirzepatide differs structurally from endogenous GIP through multiple engineered features that influence its receptor pharmacology, molecular stability, albumin association, and duration of biological activity.

Molecular & Structural Research

Tirzepatide contains a 39-residue peptide backbone based primarily on native GIP.

A simplified sequence representation is:

Y-Aib-EG-TFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS-NH₂

where Aib represents aminoisobutyric acid at positions 2 and 13. The peptide is C-terminally amidated, and the lysine residue at position 20 carries a lipid-containing side chain.

The Lys20 side chain contains γ-glutamic acid, linker units, and a C20 1,20-eicosanedioic fatty diacid moiety. This lipid modification promotes reversible albumin association and is a central structural feature of tirzepatide.

Its molecular formula is:

C₂₂₅H₃₄₈N₄₈O₆₈

with an average molecular mass of approximately:

4,813.5 g/mol

Tirzepatide is associated with CAS Number 2023788-19-2.

Research Applications

Tirzepatide may be studied in appropriately designed laboratory research involving:

• GIP receptor signaling
• GLP-1 receptor signaling
• Dual incretin receptor pharmacology
• GPCR activation and signaling
• Peptide-receptor interaction studies
• Glucose-responsive endocrine signaling
• Pancreatic islet signaling research
• Insulin-associated cellular pathways
• Glucagon-associated signaling
• Metabolic pathway regulation
• Receptor selectivity studies
• Lipidated peptide research
• Albumin-binding peptide design
• Peptide stability and structure-function research
• Comparative incretin peptide research
• Analytical peptide characterization

FDA pharmacology documentation characterizes tirzepatide as an agonist of both GIPR and GLP-1R, making dual-incretin receptor signaling one of its defining research properties.

These categories describe areas of scientific investigation and do not constitute therapeutic or clinical-use recommendations.

Preclinical Research Context

Tirzepatide has been investigated extensively in receptor-expression systems, biochemical studies, animal models, and human clinical research.

Experimental work has examined its effects on GIPR and GLP-1R activation, glucose-dependent endocrine signaling, insulin and glucagon-associated pathways, peptide pharmacokinetics, and broader metabolic signaling systems.

Structural and pharmacological characterization has also examined how its Aib substitutions, C-terminal amidation, and C20 fatty-acid side chain influence stability, receptor activity, and molecular behavior relative to endogenous incretin peptides.

Experimental findings should be interpreted within the specific model, assay conditions, receptor system, and limitations of each study and should not be assumed to establish effects for an individual Amino Apex research-material lot.

Analytical Documentation

Amino Apex provides batch-specific analytical documentation for tested lots. Individual lot documentation may include chromatographic purity analysis and other analytical information associated with the tested sample.

Because analytical characteristics may differ by production lot, the Certificate of Analysis for the applicable batch should be used as the source of measured purity and quality-control results.

Refer to the COA panel on this page or the Amino Apex COA Library for available batch documentation.

Storage & Laboratory Handling

This material should be handled only by qualified personnel using procedures appropriate for laboratory peptide materials.

Storage and handling should follow the conditions specified in the applicable product and batch documentation.

Experimental preparation, concentration, assay conditions, and analytical methodology should be established by qualified researchers according to the requirements of their specific laboratory system.

Research Use Only

For laboratory research use only.

This material is not intended for human or animal use. It is not intended for diagnostic, therapeutic, food, cosmetic, or household applications and is not intended to diagnose, treat, cure, prevent, or mitigate any disease or medical condition.